Tenaya Therapeutics (TNYA) Competitors $0.84 -0.02 (-2.74%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. ARVN, SEPN, PHAT, TSHA, VALN, PGEN, RAPP, OPT, ORKA, and ATYRShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Arvinas (ARVN), Septerna (SEPN), Phathom Pharmaceuticals (PHAT), Taysha Gene Therapies (TSHA), Valneva (VALN), Precigen (PGEN), Rapport Therapeutics (RAPP), Opthea (OPT), Oruka Therapeutics (ORKA), and aTyr Pharma (ATYR). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Arvinas Septerna Phathom Pharmaceuticals Taysha Gene Therapies Valneva Precigen Rapport Therapeutics Opthea Oruka Therapeutics aTyr Pharma Arvinas (NASDAQ:ARVN) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Which has more volatility & risk, ARVN or TNYA? Arvinas has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500. Is ARVN or TNYA more profitable? Tenaya Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -10.92%. Arvinas' return on equity of -7.74% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-10.92% -7.74% -4.11% Tenaya Therapeutics N/A -92.20%-74.53% Which has higher valuation and earnings, ARVN or TNYA? Tenaya Therapeutics has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$263.40M2.17-$198.90M-$0.66-11.89Tenaya TherapeuticsN/AN/A-$111.13M-$1.16-0.73 Do analysts prefer ARVN or TNYA? Arvinas currently has a consensus price target of $20.29, suggesting a potential upside of 158.63%. Tenaya Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 642.28%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ARVN or TNYA? 95.2% of Arvinas shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 4.7% of Arvinas shares are held by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor ARVN or TNYA? In the previous week, Arvinas had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Arvinas and 1 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.87 beat Arvinas' score of 0.53 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Arvinas Positive Tenaya Therapeutics Very Positive SummaryTenaya Therapeutics beats Arvinas on 8 of the 15 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.81M$3.02B$5.70B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-0.7320.9027.9419.99Price / SalesN/A332.33456.59102.06Price / CashN/A43.2336.5558.97Price / Book0.798.228.585.86Net Income-$111.13M-$55.19M$3.24B$258.50M7 Day Performance-4.00%5.21%3.67%1.89%1 Month Performance22.03%16.91%10.24%12.18%1 Year Performance-78.90%4.19%34.02%18.94% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.82 of 5 stars$0.84-2.7%$6.25+642.3%-77.2%$136.81MN/A-0.73110Positive NewsARVNArvinas4.0032 of 5 stars$7.52+2.3%$20.29+169.8%-72.7%$548.89M$263.40M-11.39420News CoverageUpcoming EarningsSEPNSepterna1.8392 of 5 stars$12.31-1.9%$26.75+117.3%N/A$548.53M$1.08M0.00N/APositive NewsPHATPhathom Pharmaceuticals4.3157 of 5 stars$7.83-1.5%$17.50+123.5%-21.0%$546.61M$55.25M-1.49110Positive NewsTSHATaysha Gene Therapies4.2417 of 5 stars$2.53-1.6%$8.17+222.8%+15.6%$543.09M$8.33M-7.44180VALNValneva1.9705 of 5 stars$6.35-3.1%$15.50+144.1%+5.9%$540.32M$183.52M-5.34700News CoverageGap UpPGENPrecigen3.9342 of 5 stars$1.83+4.0%$6.00+227.9%-2.1%$540.18M$4.20M-3.27190Positive NewsRAPPRapport Therapeutics1.5469 of 5 stars$14.39-2.0%$28.00+94.6%-17.8%$525.24MN/A-4.17N/AOPTOpthea0.3953 of 5 stars$3.41+7.2%$1.33-60.9%+50.9%$524.83M$120K0.008Gap UpORKAOruka Therapeutics2.7117 of 5 stars$13.77-5.3%$40.38+193.2%N/A$515.55MN/A-3.05N/AUpcoming EarningsAnalyst ForecastATYRaTyr Pharma2.1851 of 5 stars$5.71-4.7%$20.20+253.8%+187.6%$508.19M$230K-7.0553Gap UpHigh Trading Volume Related Companies and Tools Related Companies Arvinas Competitors Septerna Competitors Phathom Pharmaceuticals Competitors Taysha Gene Therapies Competitors Valneva Competitors Precigen Competitors Rapport Therapeutics Competitors Opthea Competitors Oruka Therapeutics Competitors aTyr Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
